Tenderwize
Retour à la recherche

Open-house drug rebate agreements Brandenburg

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 131 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Brandenburg

57/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

57 / 100

Complexité

61 / 100

Facteurs de risque

The lot descriptions state a latest contract-conclusion date of 21 February 2026, whereas the structured/XML deadline i...

No estimated value, quantities, expected demand or guaranteed volume is disclosed in the provided data, so potential re...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Nordost - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Feb 21, 2027

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 3 lots
  • Duration until Apr 2027
  • Conclusion of non-exclusive drug discount agreements under Section 130a(8c) SGB V for the Brandenburg statutory health-insurance region.
  • Supply-related scope covering pharmacy-prepared parenteral oncology preparations made from finished medicinal products for immediate physician administration to patients.
Afficher le résumé complet

Open-house pharmaceutical discount agreements under Section 130a(8c) SGB V for the Brandenburg statutory health-insurance region, covering Bevacizumab, Rituximab and Trastuzumab. The buyer states that every interested pharmaceutical company meeting the published requirements may join on identical, non-negotiable terms and that no supplier selection is made. Contracts are planned from 1 May 2026 to 30 April 2027, subject to earlier termination or automatic suspension if a relevant nationwide or regional discount agreement enters into force. Procurement documents are referenced through the DTVP portal but were not provided for analysis. The structured final deadline is 21 February 2027, while the lot descriptions state that contract conclusion is possible only until 21 February 2026; this material inconsistency must be clarified.

Risques

The lot descriptions state a latest contract-conclusion date of 21 February 2026, whereas the structured/XML deadline i...

No estimated value, quantities, expected demand or guaranteed volume is disclosed in the provided data, so potential re...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Only pharmaceutical companies may participate as potential contract partners.
  • The contract terms are pre-established, identical and not individually negotiable.

Administrative

  • The completed and signed agreement must be submitted together with the completed PZN file named OHV_8c_Brandenburg_Festlegung_[Wirkstoffname]_PZN.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Potsdam, DEU

Site web

www.aok.de

Identifiant

DE275390265

Activité

Health

Lots (3)

LOT-0001

Bevacizumab

Open-house, non-exclusive pharmaceutical discount agreement for Bevacizumab (ATC L01FG01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

LOT-0002

Rituximab

Open-house, non-exclusive pharmaceutical discount agreement for Rituximab (ATC L01FA01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

LOT-0003

Trastuzumab

Open-house, non-exclusive pharmaceutical discount agreement for Trastuzumab (ATC L01FD01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

Détails de la procédure

Date de publication
11 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
100552-2026

Documents (2)

Appels d'offres similaires